Moteur de recherche d’entreprises européennes
Financement de l’UE (55 M €) : Études sur la médecine novatrice de l’autisme – 2 – Essais Hor01/06/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Études sur la médecine novatrice de l’autisme – 2 – Essais
Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental condition affecting over five million people in the European Union. The combination of core symptoms (deficits in social-communication and repetitive and restricted behaviours and interests) and common comorbidities (e.g. epilepsy and depression) significantly reduces the quality of life and life-span of affected individuals. Currently there are no effective drug treatments for the core symptoms. Key factors that have hampered progress include; 1) limited understanding of the underlying pathophysiolog(ies); 2) lack of successful translation from animal models to humans; 3) testing of drugs with specific actions in biologically heterogeneous populations; 4) limited expertise of many European ASD centres in running large-scale clinical trials; and 5) trial designs (e.g. placebo effects). Our vision, therefore, is to apply a precision medicine approach to ASD and improve patient outcomes by tailoring treatments to a patient’s biological profile. Our efforts will build on the achievements of 5 other IMI initiatives, 4 Horizon 2020 networks, and 6 SMEs for the first time to; 1) align global resources to validate and qualify stratification biomarkers from infancy to adulthood; 2) develop objective outcome measures that can be used in trials; 3) create a European-wide clinical trials network that reliably carries out studies able to support filings to the EMA/FDA; 4) carry out better targeted clinical trials linked to other international efforts – including quick wins or “fast fails” of ineffective agents; 5) translate molecular mechanisms and drug effects between preclinical models and particular subtypes of ASD. Together we will bring Europe to the forefront of clinical research in ASD. Also we will provide a sustainable legacy that is accessible by others across the world, attracts industry into ASD, and helps transform healthcare.
| ARTTIC INNOVATION GmbH | 0,00 € |
| Arttic | 676 419 € |
| Assistance Publique Hopitaux de Paris | 1 027 102 € |
| 3 000,00 € | |
| 0,00 € | |
| Autisme-Europe Aisbl | 267 470 € |
| 0,00 € | |
| Biosci Consulting BVBA | 192 344 € |
| Birkbeck College - University of London | 3 039 131 € |
| 24 125 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 1 056 714 € |
| 0,00 € | |
| 0,00 € | |
| 480 469 € | |
| 0,00 € | |
| 0,00 € | |
| Demcon Production B.V. | 0,00 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| Fondazione Stella Maris | 68 125 € |
| Fundacio Privada Per A La Recerca i La Docencia Sant Joan de DEU | 3 000,00 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 216 833 € |
| 68 125 € | |
| 0,00 € | |
| Guys and St Thomas' NHS Foundationtrust | 3 000,00 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Institut National de la Sante et de la Recherche Medicale | 847 916 € |
| Institut Pasteur | 2 661 581 € |
| 3 000,00 € | |
| JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN | 780 203 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| 208 750 € | |
| Karolinska Institutet | 1 199 067 € |
| King's College London | 19,8 M € |
| 0,00 € | |
| NOVARTIS PHARMA AG | 0,00 € |
| Noldus Information Technology B.V. | 271 353 € |
| Ospedale Pediatrico Bambino Gesu | 3 000,00 € |
| Rijksuniversiteit Groningen | 833 975 € |
| 5 397 646 € | |
| Starlab Barcelona SL | 122 500 € |
| 667 778 € | |
| 187 499 € | |
| Stichting Radboud Universitair Medisch Centrum | 4 465 007 € |
| 0,00 € | |
| TEVA PHARMACEUTICAL INDUSTRIES Ltd. | 0,00 € |
| 390 695 € | |
| 0,00 € | |
| The Chancellor Masters and Scholars of the University of Cambridge | 2 797 033 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 751 011 € |
| The University of Edinburgh | 37 062 € |
| UCB Biopharma | 0,00 € |
| UNIVERSIDADE DE COIMBRA | 777 016 € |
| UNIVERSITAET ULM | 802 188 € |
| UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS | 68 125 € |
| 1 199 929 € | |
| UNIVERSITATSKLINIKUM HEIDELBERG | 3 000,00 € |
| Universidad de Salamanca | 181 731 € |
| Universitair Medisch Centrum Utrecht | 1 097 648 € |
| Universiteit Gent | 954 429 € |
| 51 813 € | |
| University of Glasgow | 138 969 € |
| University of Newcastle Upon Tyne | 138 969 € |
| Uppsala Universitet | 149 995 € |
| 920 245 € |
https://cordis.europa.eu/project/id/777394
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ARTTIC INNOVATION GmbH - Financement de l’UE (55 M €) : Études sur la médecine novatrice de l’autisme – 2 – Essais"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
